{"id":"W3159335234","doi":"10.2147/ott.s291801","title":"A Phase I Trial of the MET/ALK/ROS1 Inhibitor Crizotinib Combined with the VEGF Inhibitor Pazopanib in Patients with Advanced Solid Malignancies","year":2021,"lang":"en","type":"article","venue":"OncoTargets and Therapy","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":3,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Chugai Pharmaceutical; Merck Sharp and Dohme; EMD Serono; Genentech; Plexxikon; Bausch Health; STCube; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Silverback Therapeutics; Daiichi Sankyo Europe; National Cancer Institute; Calithera Biosciences; Aminex Therapeutics; Agios Pharmaceuticals; IFM Therapeutics; Symphogen; Pfizer; Incyte; Boston Pharmaceuticals; Five Prime Therapeutics; Loxo Oncology; Astex Pharmaceuticals; Eli Lilly and Company; National Comprehensive Cancer Network; Principia Biopharma; University of Texas MD Anderson Cancer Center; Puma Biotechnology; National Institutes of Health; BioMarin Pharmaceutical; Regeneron Pharmaceuticals; Baxalta; Immune Deficiency Foundation; Helsinn; Exelixis; Karyopharm Therapeutics; Bristol-Myers Squibb; American Society of Clinical Oncology; Sanofi; Amgen","keywords":"Crizotinib; Pazopanib; Medicine; ROS1; Internal medicine; Oncology; Tyrosine-kinase inhibitor; Progressive disease; Gastroenterology; Pharmacology; Cancer; Sunitinib; Chemotherapy; Lung cancer; Adenocarcinoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008414033,0.0001835987,0.0003592825,0.00003418144,0.0001351988,0.00002361498,0.00006053576,0.00004126937,0.0000313661],"category_scores_gemma":[0.00001760909,0.00007797466,0.00006446234,0.0002655728,0.000142677,0.00008182211,0.00002202949,0.0001230216,5.826543e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004363253,"about_ca_system_score_gemma":0.0002851941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002806951,"about_ca_topic_score_gemma":0.00007838228,"domain_scores_codex":[0.9989591,0.00006969245,0.0002324717,0.000240294,0.0002991408,0.0001992899],"domain_scores_gemma":[0.9992362,0.0000582908,0.0001484181,0.0002947751,0.0002005424,0.000061756],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.5137051,0.04015978,0.2121684,0.0002986418,0.003122848,0.0001983206,0.02345299,0.00005911438,0.04598664,0.001865395,0.001936738,0.157046],"study_design_scores_gemma":[0.7699222,0.04153588,0.09554537,0.0007438713,0.0004205298,0.00001286673,0.001978557,0.00001703576,0.06427233,0.0001806953,0.02495773,0.0004129509],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9955321,0.001094573,0.000006831224,0.001431472,0.0002088142,0.00130776,0.00004456858,0.00001365049,0.0003602168],"genre_scores_gemma":[0.9984314,0.0002260399,0.0002418166,0.0005053365,0.0000934362,0.0001275817,0.00004042409,0.0000261175,0.0003078609],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2562172,"threshold_uncertainty_score":0.3179714,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00900558308648964,"score_gpt":0.2918006701008566,"score_spread":0.282795087014367,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}